A BILL 
To amend the Controlled Substances Act to make marijuana 
accessible for use by qualified marijuana researchers for 
medical purposes, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medical Marijuana Re-
4
search Act of 2019’’. 
5
01:50 Jul 31, 2019
H3797
2 
•HR 3797 IH
SEC. 2. PRODUCTION AND SUPPLY. 
1
(a) IN GENERAL.—The Secretary of Health and 
2
Human Services— 
3
(1) until the date on which the Secretary deter-
4
mines that manufacturers and distributors (other 
5
than the Federal Government) can ensure a suffi-
6
cient supply of marijuana for qualified marijuana re-
7
searchers intended for medical research, shall— 
8
(A) continue to produce marijuana through 
9
the National Institute on Drug Abuse (NIDA) 
10
Drug Supply Program; and 
11
(B) offer for sale immature marijuana 
12
plants and the seeds of marijuana— 
13
(i) to all qualified marijuana research-
14
ers who submit a request for such plants 
15
or seeds to engage in research pursuant to 
16
the section 303(f)(3) of the Controlled 
17
Substances Act, as amended by section 3; 
18
and 
19
(ii) in quantities sufficient to produce 
20
an adequate supply of marijuana for such 
21
research; and 
22
(2) beyond the date specified in paragraph (1), 
23
may, at the Secretary’s discretion, continue to so 
24
produce and supply marijuana. 
25
01:50 Jul 31, 2019
H3797
3 
•HR 3797 IH
(b) REQUIREMENT TO VERIFY REGISTRATION.—Be-
1
fore supplying marijuana to any person through the Na-
2
tional Institute on Drug Abuse Drug Supply Program, the 
3
Secretary of Health and Human Services shall— 
4
(1) require the person to submit documentation 
5
demonstrating that the person is a qualified mari-
6
juana researcher seeking to conduct research pursu-
7
ant to section 303(f)(3) of the Controlled Substances 
8
Act, as amended by section 3; and 
9
(2) not later than 30 days after receipt of such 
10
documentation, review such documentation and 
11
verify that the marijuana will be used for such re-
12
search (and for no other purpose authorized pursu-
13
ant to this Act). 
14
(c) GUIDELINES
ON PRODUCTION.—The Commis-
15
sioner of Food and Drugs, in consultation with the Direc-
16
tor of the National Institute on Drug Abuse, shall— 
17
(1) not later than 180 days after the date of 
18
enactment of this Act, issue guidelines on the pro-
19
duction of marijuana by qualified marijuana re-
20
searchers pursuant to subsection (a)(1)(B); and 
21
(2) encourage researchers and manufacturers 
22
that are authorized to produce or manufacture mari-
23
juana pursuant to section 303 of the Controlled 
24
Substances Act (21 U.S.C. 823), as amended by this 
25
01:50 Jul 31, 2019
H3797
4 
•HR 3797 IH
Act, to comply with such guidelines to the extent ap-
1
plicable. 
2
(d) DEFINITION.—In this section: 
3
(1) The term ‘‘immature marijuana plant’’ 
4
means a marijuana plant with no observable flowers 
5
or buds. 
6
(2) The term ‘‘qualified medical marijuana re-
7
searcher’’ means a researcher who is registered to 
8
conduct research with marijuana under section 
9
303(f)(3) of the Controlled Substances Act, as 
10
amended by section 3. 
11
SEC. 3. FACILITATING MARIJUANA RESEARCH. 
12
(a) IN GENERAL.—Section 303(f) of the Controlled 
13
Substances Act (21 U.S.C. 823(f)) is amended— 
14
(1) by redesignating paragraphs (1) through 
15
(5) as subparagraphs (A) through (E), respectively; 
16
(2) by striking ‘‘(f) The Attorney General’’ and 
17
inserting ‘‘(f)(1) The Attorney General’’; 
18
(3) by striking ‘‘Registration applications’’ and 
19
inserting the following: 
20
‘‘(2) Registration applications’’; 
21
(4) in paragraph (2), as so designated, by strik-
22
ing ‘‘schedule I’’ each place that term appears and 
23
inserting ‘‘schedule I, except marijuana,’’; 
24
01:50 Jul 31, 2019
H3797
5 
•HR 3797 IH
(5) by striking ‘‘Article 7’’ and inserting the 
1
following: 
2
‘‘(4) Article 7’’; and 
3
(6) by inserting before paragraph (4), as so 
4
designated, the following: 
5
‘‘(3)(A) The Attorney General shall register a practi-
6
tioner to conduct research with marijuana if— 
7
‘‘(i) the applicant is authorized to dispense, or 
8
conduct research with respect to, controlled sub-
9
stances in schedules II, III, IV, and V under the 
10
laws of the State in which the applicant practices; 
11
‘‘(ii) the applicant is only using marijuana man-
12
ufactured by a person registered under subsection 
13
(l); 
14
‘‘(iii) the applicant’s research protocol— 
15
‘‘(I) has been reviewed and allowed by— 
16
‘‘(aa) the Secretary under section 
17
505(i) of the Federal Food, Drug, and 
18
Cosmetic Act (21 U.S.C. 355(i)); or 
19
‘‘(bb) the National Institutes of 
20
Health or another Federal agency that 
21
funds scientific research; or 
22
‘‘(II) in the case of nonhuman research 
23
that is not federally funded, has been volun-
24
tarily submitted by the applicant to, and ap-
25
01:50 Jul 31, 2019
H3797
6 
•HR 3797 IH
proved by, the National Institutes of Health; 
1
and 
2
‘‘(iv) the applicant has demonstrated that there 
3
are effective procedures in place to adequately safe-
4
guard against diversion of the marijuana from legiti-
5
mate medical or scientific use, in accordance with 
6
subparagraph (E). 
7
‘‘(B) The Attorney General shall grant an application 
8
for registration under this paragraph unless the Attorney 
9
General determines that the issuance of the registration 
10
would be inconsistent with the public interest. In deter-
11
mining the public interest, the following factors shall be 
12
considered: 
13
‘‘(i) The applicant’s experience in dispensing, or 
14
conducting research with respect to, controlled sub-
15
stances. 
16
‘‘(ii) The applicant’s conviction record under 
17
Federal or State laws relating to the manufacture, 
18
distribution, or dispensing of controlled substances. 
19
‘‘(iii) Compliance with applicable State or local 
20
laws relating to controlled substance misuse or diver-
21
sion. 
22
‘‘(C) Not later than 90 days after the date of enact-
23
ment of the Medical Marijuana Research Act of 2019, for 
24
01:50 Jul 31, 2019
H3797
7 
•HR 3797 IH
purposes of subparagraph (A)(ii)(II), the National Insti-
1
tutes of Health shall establish a process that— 
2
‘‘(i) allows a researcher to voluntarily submit 
3
the research protocol of the researcher for review 
4
and approval; and 
5
‘‘(ii) provides a researcher described in clause 
6
(i) with a decision not less than 30 days after the 
7
date on which the research protocol is submitted. 
8
‘‘(D)(i) Not later than 60 days after the date on 
9
which the Attorney General receives a complete applica-
10
tion for registration under this paragraph, the Attorney 
11
General shall approve or deny the application. 
12
‘‘(ii) For purposes of clause (i), an application shall 
13
be deemed complete when the applicant has submitted 
14
documentation showing that the requirements under sub-
15
paragraph (A) are satisfied. 
16
‘‘(iii) In the case of a denial under clause (i), the At-
17
torney General shall provide a written explanation of the 
18
basis for the denial and a description of any curative steps 
19
that may be taken for such request to be approved. 
20
‘‘(E)(i) A researcher registered under this paragraph 
21
shall store marijuana to be used in research in a securely 
22
locked, substantially constructed cabinet. 
23
‘‘(ii) Except as provided in clause (i), any security 
24
measures required by the Attorney General for practi-
25
01:50 Jul 31, 2019
H3797
8 
•HR 3797 IH
tioners conducting research with marijuana pursuant to 
1
a registration under this paragraph shall be consistent 
2
with the security measures for practitioners conducting re-
3
search on other controlled substances in schedule II that 
4
have a similar risk of diversion and abuse. 
5
‘‘(F)(i) If the Attorney General grants an application 
6
for registration under this paragraph, the applicant may 
7
amend or supplement the research protocol without re-
8
applying if the applicant does not— 
9
‘‘(I) change the type of drug, the source of the 
10
drug, or the conditions under which the drug is 
11
stored, tracked, or administered; or 
12
‘‘(II) otherwise increase the risk of diversion. 
13
‘‘(ii) If an applicant amends or supplements the re-
14
search protocol or initiates research on a new research 
15
protocol under clause (i), the applicant shall, in order to 
16
renew the registration under this paragraph, provide no-
17
tice to the Attorney General of the amended or supple-
18
mented research protocol or any new research protocol in 
19
the applicant’s renewal materials. 
20
‘‘(iii)(I) If an applicant amends or supplements a re-
21
search protocol and the amendment or supplement in-
22
volves a change to the type of drug, the source of the drug, 
23
or conditions under which the drug is stored, tracked, or 
24
administered or otherwise increases the risk of diversion, 
25
01:50 Jul 31, 2019
H3797
9 
•HR 3797 IH
the applicant shall provide notice to the Attorney General 
1
not later than 30 days before proceeding on such amended 
2
or supplemental research or new research protocol, as the 
3
case may be. 
4
‘‘(II) If the Attorney General does not object during 
5
the 30-day period following a notification under subclause 
6
(I), the applicant may proceed with the amended or sup-
7
plemental research or new research protocol. 
8
‘‘(iv) The Attorney General may object to an amend-
9
ed or supplemental protocol or a new research protocol 
10
under clause (i) or (iii) only if additional security meas-
11
ures are needed to safeguard against diversion or abuse. 
12
‘‘(G) If marijuana or a compound of marijuana is 
13
listed on a schedule other than schedule I, the provisions 
14
of paragraphs (1), (2), and (4) that apply to research with 
15
a controlled substance in the applicable schedule shall 
16
apply to research with marijuana or that compound, as 
17
applicable, in lieu of the provisions of subparagraphs (A) 
18
through (G) of this paragraph.’’. 
19
(b) CONFORMING AMENDMENT.—Section 102(16) of 
20
the Controlled Substances Act (21 U.S.C. 802(16)) is 
21
amended by inserting ‘‘or ‘marijuana’ ’’ after ‘‘The term 
22
‘marihuana’ ’’. 
23
01:50 Jul 31, 2019
H3797
10 
•HR 3797 IH
SEC. 4. MANUFACTURE AND DISTRIBUTION OF MARIJUANA 
1
FOR 
USE 
IN 
LEGITIMATE, 
MEDICAL 
RE-
2
SEARCH. 
3
Section 303 of the Controlled Substances Act (21 
4
U.S.C. 823), as amended by section 3, is further amended 
5
by adding at the end the following: 
6
‘‘(l) REGISTRATION OF PERSONS TO MANUFACTURE 
7
AND DISTRIBUTE MARIJUANA FOR USE IN LEGITIMATE, 
8
MEDICAL RESEARCH.— 
9
‘‘(1) REGISTRATION OF MANUFACTURERS.—Be-
10
ginning not later than the day that is 1 year after 
11
the date of enactment of the Medical Marijuana Re-
12
search Act of 2019, the Attorney General shall reg-
13
ister an applicant to manufacture marijuana to the 
14
extent the marijuana will be used exclusively by 
15
qualified marijuana researchers for research pursu-
16
ant to subsection (f)(3), unless the Attorney General 
17
determines that the issuance of such registration is 
18
inconsistent with the public interest. In determining 
19
the public interest, the Attorney General shall— 
20
‘‘(A) take into consideration— 
21
‘‘(i) maintenance of effective controls 
22
against diversion of marijuana and any 
23
controlled substance compounded there-
24
from into other than legitimate medical, 
25
scientific, or research channels; 
26
01:50 Jul 31, 2019
H3797
11 
•HR 3797 IH
‘‘(ii) compliance with applicable State 
1
and local laws relating to controlled sub-
2
stance misuse and diversion; and 
3
‘‘(iii) prior conviction record of the 
4
applicant under Federal or State laws re-
5
lating to the manufacture, distribution, or 
6
dispensing of such substances; and 
7
‘‘(B) not take into consideration any fac-
8
tors other than the factors listed in subpara-
9
graph (A). 
10
‘‘(2) REGISTRATION OF DISTRIBUTORS.—Begin-
11
ning not later than the day that is 1 year after the 
12
date of enactment of the Medical Marijuana Re-
13
search Act of 2019, the Attorney General shall reg-
14
ister an applicant to distribute marijuana that is in-
15
tended to be used exclusively by qualified medical 
16
marijuana researchers for research pursuant to sub-
17
section (f)(3), unless the Attorney General deter-
18
mines that the issuance of such registration is incon-
19
sistent with the public interest. 
20
‘‘(3) PUBLIC
INTEREST.—In determining the 
21
public interest under paragraph (2), the Attorney 
22
General shall— 
23
‘‘(A) take into consideration— 
24
01:50 Jul 31, 2019
H3797
12 
•HR 3797 IH
‘‘(i) maintenance of effective controls 
1
against diversion of marijuana and any 
2
controlled substance compounded there-
3
from into other than legitimate medical, 
4
scientific, or research channels; 
5
‘‘(ii) compliance with applicable State 
6
and local law; 
7
‘‘(iii) prior conviction record of the 
8
applicant under Federal or State laws re-
9
lating to the manufacture, distribution, or 
10
dispensing of such substances; and 
11
‘‘(iv) past experience in the distribu-
12
tion of controlled substances, and the exist-
13
ence in the establishment of effective con-
14
trols against diversion; and 
15
‘‘(B) not take into consideration any fac-
16
tors other than the factors listed in subpara-
17
graph (A). 
18
‘‘(4) NO LIMIT ON NUMBER OF MANUFACTUR-
19
ERS
AND
DISTRIBUTORS.—Notwithstanding any 
20
other provision of law, the Attorney General shall 
21
not impose or implement any limit on the number of 
22
persons eligible to be registered to manufacture or 
23
distribute marijuana pursuant to paragraph (1) or 
24
(2). 
25
01:50 Jul 31, 2019
H3797
13 
•HR 3797 IH
‘‘(5) REQUIREMENT TO VERIFY USE FOR LE-
1
GITIMATE, MEDICAL RESEARCH.—As a condition on 
2
registration under this section to manufacture or 
3
distribute marijuana, the Attorney General shall re-
4
quire the registrant— 
5
‘‘(A) to require any person to whom the 
6
marijuana will be supplied to submit docu-
7
mentation demonstrating that the marijuana 
8
will be used exclusively by qualified medical 
9
marijuana researchers for research pursuant to 
10
subsection (f)(3); 
11
‘‘(B) in the case of distribution, to com-
12
plete, with respect to that distribution, the 
13
DEA Controlled substance order form (DEA 
14
222) (or a successor form) and the DEA Cer-
15
tificate of Registration (DEA Form 223) (or a 
16
successor form) and to upload such forms to 
17
the system used by the Drug Enforcement 
18
Agency for such distribution; 
19
‘‘(C) to include in the labeling of any mari-
20
juana so manufactured or distributed— 
21
‘‘(i) the following statement: ‘This 
22
material is for medical and scientific re-
23
search purposes only.’; and 
24
01:50 Jul 31, 2019
H3797
14 
•HR 3797 IH
‘‘(ii) the name of the requestor of the 
1
marijuana; and 
2
‘‘(D) not later than 30 days after receipt 
3
of such documentation, and before supplying 
4
the marijuana to such person, to review such 
5
documentation and verify that the marijuana 
6
will be so used. 
7
‘‘(6) TIMING.—Not later than 30 days after re-
8
ceipt of a request for registration under this sub-
9
section to manufacture or distribute marijuana, the 
10
Attorney General shall— 
11
‘‘(A) grant or deny the request; and 
12
‘‘(B) in the case of a denial, provide a 
13
written explanation of the basis for the denial 
14
and a description of any curative steps that 
15
may be taken for such request to be approved. 
16
‘‘(7) DEEMED
APPROVAL.—If the Attorney 
17
General fails to grant or deny a request for registra-
18
tion under this subsection to manufacture or dis-
19
tribute marijuana within the 30-day period referred 
20
to in paragraph (5), such request is deemed ap-
21
proved. 
22
‘‘(8) DEFINITION.—For purposes of this sub-
23
section, the term ‘qualified medical marijuana re-
24
searcher’ means a researcher who is registered to 
25
01:50 Jul 31, 2019
H3797
15 
•HR 3797 IH
conduct research with marijuana under subsection 
1
(f)(3).’’. 
2
SEC. 5. TERMINATION OF INTERDISCIPLINARY REVIEW 
3
PROCESS FOR NON-NIH-FUNDED RESEARCH-
4
ERS. 
5
The Secretary of Health and Human Services may 
6
not— 
7
(1) reinstate the Public Health Service inter-
8
disciplinary review process described in the guidance 
9
entitled ‘‘Guidance on Procedures for the Provision 
10
of Marijuana for Medical Research’’ (issued on May 
11
21, 1999); or 
12
(2) create an additional review of scientific pro-
13
tocols that is only conducted for research on mari-
14
juana other than the review of research protocols 
15
performed at the request of a researcher conducting 
16
nonhuman research that is not federally funded, in 
17
accordance with section 303(f)(3)(A)(ii)(II) of the 
18
Controlled 
Substances 
Act 
(21 
U.S.C. 
19
823(f)(3)(A)(ii)(II)), as amended by section 3. 
20
SEC. 6. CONSIDERATION OF RESULTS OF RESEARCH. 
21
Immediately upon the approval by the Food and 
22
Drug Administration of an application for a marijuana- 
23
based drug under section 505 of the Federal Food, Drug, 
24
and Cosmetic Act (21 U.S.C. 355), and (irrespective of 
25
01:50 Jul 31, 2019
H3797
16 
•HR 3797 IH
whether any such approval is granted) not later than the 
1
date that is 5 years after the date of enactment of this 
2
Act, the Secretary of Health and Human Services shall— 
3
(1) conduct a review of existing medical and 
4
other research with respect to marijuana; 
5
(2) submit a report to the Congress on the re-
6
sults of such review; and 
7
(3) include in such report whether, taking into 
8
consideration the factors listed in section 201(c) of 
9
the Controlled Substances Act (21 U.S.C. 811(c)), 
10
as well as any potential for medical benefits, any 
11
gaps in research, and any impacts of Federal restric-
12
tions and policy on research, marijuana should be 
13
transferred to a schedule other than schedule I (if 
14
marijuana has not been so transferred already). 
15
SEC. 7. NO PRODUCTION QUOTAS FOR MARIJUANA GROWN 
16
FOR LEGITIMATE, SCIENTIFIC RESEARCH. 
17
Section 306 of the Controlled Substances Act (21 
18
U.S.C. 826) is amended by adding at the end the fol-
19
lowing: 
20
‘‘(j) The Attorney General may only establish a quota 
21
for production of marijuana that is manufactured and dis-
22
tributed in accordance with the Medical Marijuana Re-
23
search Act of 2019 that meets the changing medical, sci-
24
01:50 Jul 31, 2019
H3797
17 
•HR 3797 IH
entific, and industrial needs for marijuana (as defined by 
1
the National Institute on Drug Abuse).’’. 
2
SEC. 8. ARTICLE 28 OF THE SINGLE CONVENTION ON NAR-
3
COTIC DRUGS. 
4
Article 28 of the Single Convention on Narcotic 
5
Drugs shall not be construed to prohibit, or impose addi-
6
tional restrictions upon, research involving marijuana, or 
7
the manufacture, distribution, or dispensing of marijuana, 
8
that is conducted in accordance with the Controlled Sub-
9
stances Act (21 U.S.C. 801 et seq.), this Act, and the 
10
amendments made by this Act. 
11
SEC. 9. NO INTERFERENCE BY DEPARTMENT OF JUSTICE. 
12
The Attorney General of the United States, and any 
13
officer or employee of the Department of Justice, shall not 
14
interfere with the production, distribution, and sale of 
15
marijuana in accordance with this Act and the amend-
16
ments made by this Act. 
17
SEC. 10. DEFINITION. 
18
In this Act, the term ‘‘marijuana’’ has the meaning 
19
given to the term ‘‘marihuana’’ in section 102 of the Con-
20
trolled Substances Act (21 U.S.C. 802). 
21
Æ 
01:50 Jul 31, 2019
H3797
